MentionFox
Home › funding signals › BIOVENTRIX, INC.
Company · SEC filings

BIOVENTRIX, INC. funding history

BIOVENTRIX, INC. has 11 Form D filings on record, from 2023-01-25 to 2026-10-08. Together its new offerings report $19.06M sold.

Pitching, partnering or investing alongside them? See who really runs and owns BIOVENTRIX, INC.

Watch BIOVENTRIX, INC.

Free to see. No signup.

Funding historyFounders and team

Key facts

  • · Type: New offering first sale 2026-09-29 · Amount sold: $1.20M · Total offering: $3M · SEC filing
  • · Type: Amendment first sale 2026-04-16 · Amount sold: $2.96M · Total offering: $10M · SEC filing
  • · Type: Amendment first sale 2026-04-16 · Amount sold: $2.77M · Total offering: $10M · SEC filing
  • · Type: New offering first sale 2026-04-16 · Amount sold: $705K · Total offering: $6M · SEC filing
  • · Type: Amendment first sale 2024-10-10 · Amount sold: $6.67M · Total offering: $12M · SEC filing
Based
MANSFIELD, MASSACHUSETTS
Industry group
Biotechnology
Filings
11
Raised (new offerings)
$19.06M

Every filing

FiledTypeAmount soldTotal offeringRecords
2026-10-08New offering
first sale 2026-09-29
$1.20M$3Mdetails · SEC filing
2026-09-09Amendment
first sale 2026-04-16
$2.96M$10Mdetails · SEC filing
2026-09-01Amendment
first sale 2026-04-16
$2.77M$10MSEC filing
2026-04-24New offering
first sale 2026-04-16
$705K$6MSEC filing
2025-11-04Amendment
first sale 2024-10-10
$6.67M$12MSEC filing
2025-07-08Amendment
first sale 2024-10-10
$3.60M$7.50MSEC filing
2024-10-15New offering
first sale 2024-10-10
$125K$3MSEC filing
2024-08-29Amendment
first sale 2024-03-22
$3M$3MSEC filing
2024-03-29New offering
first sale 2024-03-22
$2.40M$2.40MSEC filing
2023-04-04New offering
first sale 2023-03-30
$12.65M$15.65MSEC filing
2023-01-25New offering
first sale 2023-01-13
$1.98M$3MSEC filing

What do you want to do with BIOVENTRIX, INC.?

Want the whole picture on BIOVENTRIX, INC.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on BIOVENTRIX, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on BIOVENTRIX, INC. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    11 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on Target: the verdict, 16 sections, 39 cited sources, dated 2026-09-28A real finished report, first screen. Opens in a new tab.

How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.

Every figure here is read from BIOVENTRIX, INC.'s own filings with the SEC. The people those filings name are on the team page.

Filings & events

Fundraising filings

IPO filings

Follow this companyRSS

Tools for this story

Each opens in a new tab, filled in for BIOVENTRIX, INC.. With no account yet, you sign up free and land on the result.

Cite this page

Permanent URL: https://mentionfox.com/company/bioventrix-inc
Last updated 2026-10-18
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
BIOVENTRIX, INC. funding history: 11 SEC filings, $19.06M raised. MentionFox, 2026-10-18. https://mentionfox.com/company/bioventrix-inc